Moreover, several studies have described higher circulating IL-18
in SLE patients than in control subjects, and the levels correlates with the anti-dsDNA titres and the SLEDAI score.[138, 140, 142, 143] Apart from the kidneys, IL-18 was also highly relevant in other organ manifestations of lupus. IL-18 was abundantly expressed in biopsy samples of lesional skin from patients with cutaneous lupus. These patients also expressed higher levels of IL-18 receptor on their keratinocyte surface in response to TNF-α and IFN-γ buy Pexidartinib stimulation. Kahlenberg et al. have recently demonstrated that inflammasome activation of IL-18 would result in endothelial progenitor cell (EPC) dysfunction in SLE patients, which might explain premature atherosclerosis in SLE. In these selleck chemical experiments, neutralization of IL-18 in SLE EPC cultures restores their capacity to differentiate into mature endothelial cells, supporting a deleterious effect of IL-18 on vascular repair in vivo. Nold et al. demonstrated that the use of a IL-18 binding protein would significantly inhibit the release of IFN-α and matrix metalloproteinase-9 (MMP-9) from whole blood samples obtained from SLE patients, and anti-IL18 might confer additional inhibitory
effect on the pro-inflammatory cytokines when compared with samples incubated with corticosteroids or mycophenolic acid alone. Although IL-18 blockade appeared to a potential therapeutic concept in SLE, the clinical data regarding this approach are still lacking. In this review, we have highlighted the cytokines which have crucial pathogenic significance in SLE (Fig. 1). The growing knowledge in these cytokines has introduced opportunities for the design of innovative diagnostics and therapeutic approaches (Table 1). Currently, these novel therapies which involve the attenuation of the cytokine system are often used as add-on treatment or for recalcitrant cases. However, one should expand the use of these biologics such as minimization of other immunosuppressive drugs which CYTH4 have more significant toxicities.
While some of these agents have proven efficacy and tolerability in the initial studies, the long-term safety remains undefined. Both upcoming randomized trials and long-term follow-up studies are needed to adequately address these concerns. Taken together, data regarding the manipulation of the cytokine systems are encouraging and it is worthwhile to invest resources for the development of therapy in this promising direction. “
“The Cochrane Collaboration is a global network whose aim is to improve health-care decision making through systematic reviews of the effects of health-care interventions. Cochrane systematic reviews are published in the Cochrane Database of Systematic Reviews within The Cochrane Library ( http://www.thecochranelibrary.